Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial

INTRODUCTION: Although many biologic therapies are effective for clearing skin of patients with psoriasis, some lose effectiveness over time. This phase 2 open-label extension (OLE) trial was designed to investigate the long-term safety and efficacy of risankizumab. METHODS: In the phase 2, double-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, Kim A., de Vente, Saskia, Zeng, Jiewei, Flack, Mary, Padilla, Byron, Tyring, Stephen K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018913/
https://www.ncbi.nlm.nih.gov/pubmed/33512666
http://dx.doi.org/10.1007/s13555-021-00490-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018913/
https://www.ncbi.nlm.nih.gov/pubmed/33512666
http://dx.doi.org/10.1007/s13555-021-00490-3

Ejemplares similares